How to access ACT-on-HCV
LiverLearning® registered users:1)Please go to:
http://liverlearning.aasld.org/aasld/2012/Curriculum/226402)Sign in with your Liver
Learning® username and password
New Users to LiverLearning® -- request an access code:
1)Please go to: http://liverlearning.aasld.org/aasld/register?vxc=%2Faasld
2)Complete the registration form and affirm your status as an eligible healthcare provider
3)Once you receive a notification that your application has been approved, sign-in with username and password provided in the notification
What is ACT-on-HCV?
AASLD Curriculum & Training (ACT) is a new initiative that will provide strategies and mentoring for managing HCV and is designed to increase the confidence and competence of healthcare professionals new to providing care for patients with HCV.
ACT on HCV Curriculum includes the following components (detailed below): five online interactive CME/CE-certified modules; an experiential component which includes logging direct clinical experiences, mentoring from "Expert Resources", and participation in case-based discussions via the ACT on HCV community teleconference/web-based programming; an online final examination, and a Certificate of Curriculum Completion for successful trainees.
Why ACT-on-HCV?
As the field of hepatology continues to grow, an increasing number of healthcare professionals with little or no experience are being utilized to provide competent patient care. Further, providers in communities or facilities with limited hepatology or Specialty Clinics may have fewer opportunities to engage in real patient cases or multi-disciplinary case discussions regarding patients with HCV. These providers need to be able to evaluate and identify patients for potential therapeutic treatment, and potentially initiate treatment when appropriate.
Who is the Target Audience for ACT?
Medical professionals new to providing care to patients with HCV.
What are the Key Topic Areas?
- A general overview of HCV
- Genotyping and predictors of response
- Patient selection
- Initiating HCV treatment and the first eight weeks
- Managing side effects of therapy
What are the Components to the Curriculum?
There are two components to the Curriculum: 1) Online Learning and 2) Experiential –- "ACTual.”
Online:
- 5 online interactive, narrated modules 30 to 45 minutes in length
- Pre- and post-test questions for each module
- Final online multiple choice evaluation
Experiential Component "ACTual":
Download the Experiential Log: Each trainee is required to log a minimum of 40 hours of clinical or direct experiences specifically with patients with viral hepatitis. These experiences are to be verified by the trainee’s Expert Resource, who is an experienced clinician / hepatologist. The expert can be self-identified, or upon request (via the participant’s registration), a link to a potential Expert Resource (AASLD member) will be provided to the trainee.
Participate in Community Teleconferences/Web-based:Trainees will be required to attend a minimum of five (5) -- ACT on HCV Community Teleconferences/Web-based conference calls with other Expert Resources and Trainees during the training period. Trainees will be required to present two (2) cases to this group, optimally with their Expert Resource in attendance.
Direct Case Management: As part of the experiential component, a minimum of two (2) cases related to the direct management of patients with HCV will be required as part of the successful completion of the experiential component.
Expert Resource Check-ins: In addition to review and support of two (2) patient cases by the trainee, the Expert Resource is required to provide interim "check-ins", review a trainee’s progress, and sign-off on the experiential log.
Upload: Upon completion of the experiential log and obtaining signatures from the Expert Resource, the trainee will scan and upload their log for verification. Upon verification a certificate of completion will be issued.
What are the Requirements to obtain a Certificate of Completion for the ACT on HCV Curriculum?
1. Trainees must score an 80% on each of the 5 modules in order to pass.
2. Trainee must complete and verify with the Expert Resource the experiential component of curriculum.
3. Upon verification of
all of the online and experiential component requirements, the trainee will receive a Certificate of Completion for the ACT-on-HCV Curriculum.
What are the Requirements for Successful Completion of CME/CE Credits?
In order to receive credit, participants must view and engage in the individual online modules, complete the pre- and post-tests, and the module evaluation form. This program is offered free of charge for educational purposes to healthcare professionals and others interested in the treatment of patients with hepatitis C.
Media: Internet
Release date: November 10, 2012
Expiration date: November 10, 2013
Time to complete each module: 45 minutes
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education(ACCME)to provide continuing medical education for physicians. The Institute for Advancement of Human Behavior (IAHB) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This material is co-provided by IAHB and AASLD.
Credit Designation
AASLD designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
IAHB designates this enduring material for a maximum of 3.75 contact hours.
Learning Objectives:
- Module 1: HCV Overview
- Discuss the natural history of hepatitis C infection
- Describe treatment guidelines in genotype 1 infection with direct-acting anti-viral agents
- Module 2: HCV Genotyping and Predictors of Response
- Understand the role of hepatitis C genotyping in the treatment of chronic hepatitis C
- Identify both patient and viral factors that affect response to hepatitis C antiviral therapy
- Predict response rates in patients who did not achieve a sustained virological response (SVR) to prior therapy
- Describe a patient's chances of achieving SVR
- Module 3: Patient Selection
- Identify 3 barriers to treatment of chronic hepatitis C
- Identify 3 factors that can negatively impact a patient’s response to treatment
- Demonstrate understanding of the role of a multidisciplinary team in the treatment of patients with chronic hepatitis C
- Module 4: Initiating HCV Treatment: The first 8 Weeks
- Describe the proper use and management of hepatitis C protease inhibitors, peginterferon and ribavirin for the treatment of chronic HCV genotype 1 infection
- Identify monitoring and laboratory tests relevant to HCV managment
- Develop strategies to minimize adverse effects related to HCV antiviral treatment
- Module 5: Managing Side Effects of Therapy
- Discuss interventions for side effect management during hepatitis C treatment
Faculty Disclosure of Conflict of Interest
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
The organizer and faculty have reported the following disclosures:
Currie, Sue, EdD, MA
Organizer
Employment: Health Interactions
Baytarian, Michelle, PA-C, MMSC
Nothing to disclose
Content of presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s)
Gilles, HoChong, RN, MS, FNP-C
Nothing to disclose
Content of presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s)
Surdy, Michael J., PharmD, AAHIVP
Nothing to disclose
Content of presentation does include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s)
Wetmore, Michele, MSN, ANP-BC, NP-C
Nothing to disclose
Content of presentation does include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s)
Yee, Helen S., PharmD
Nothing to disclose
Content of presentation does include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s)
The planners reported the following disclosures:
Angulo, Paul, MD
Grant/Research Support: NIH
Chrobak, Berni, MSN, MBA, RN
Nothing to disclose
Hauch, Lois, FNP
Nothing to disclose
Haynes-Williams, Vanessa, MSN
Nothing to disclose
Horne, Patrick, MSN, ARNP
Scientific Consultant: Vertex
Grant/Research Support: Bayer/Onyx
Latimer, Dustin, PA-C
Speaking and Teaching: Vertex
Grant/Research Support: AASLD NP/PA Fellowship
Lippello, Anita, CRNP, MSN
Nothing to disclose
Luber, Andrew, PharmD
Nothing to disclose
McCurdy, Heather, RN
Speaking and Teaching: Onyx/Bayer
Panther, Mary, BSN, RN
Stock: Merck
Peter, Joy, RN, BSN
Nothing to disclose
Senecal, Douglas, PA-C
Nothing to disclose
Slazinski, Karen, PharmD
Nothing to disclose
Stadheim, Linda, RN
Nothing to disclose
Terrault, Norah, MD
Leadership: Liver Transplantation, Deputy Editor
Scientific Consultant: Roche, SciClone
Advisory Board: Vertex
Grant/Research Support: Gilead, Roche, Vertex, Eisai, Novartis
Thornton, Karla, MD
Nothing to disclose
Wentworth, Corinne, PA-C
Scientific Consultant: Merck
Advisory Board: Merck, Vertex
Speaking and Teaching: Merck, Vertex, Genetech, Bayer/Onyx, Clinical Care Options, Scripps, Gilead
Disclosure of Off-Label Use
This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Acknowledgment of Commercial Support: No commercial support was received for this enduring material activity.